Sunshine Biopharma Inc expected to post a loss of 11 cents a share - Earnings Preview

Sunshine Biopharma

12/08/2025 21:59

Sunshine Biopharma Inc SBFM.OQ SBFM.O is expected to  show a rise in quarterly revenue when it reports  results on August 14 (estimated) for the period ending June 30 2025

The Fort Lauderdale Florida-based  company is expected to report a 20.4% increase in revenue to $11.2 million from $9.3 million a year ago, according to the estimate from one analyst, based on LSEG data.

​LSEG's mean analyst estimate for Sunshine Biopharma Inc is for a loss of 11 cents per share.

The one available analyst rating on the shares is "buy".

The average consensus recommendation for the pharmaceuticals peer group is also "Buy".​

Wall Street's median 12-month price target for Sunshine Biopharma Inc is $7.00, about 79.6% above its last closing price of $1.43

This summary was machine generated August 12 at 20:59 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)